NeoImmuneTech, Inc.
A clinical-stage biopharma developing T cell-focused immuno-therapeutics for diseases.
950220 | KO
Overview
Corporate Details
- ISIN(s):
- KR8840140006
- LEI:
- Country:
- United States of America
- Address:
- 2400 Research Boulevard, Suite 250, Rockville, MD 20850, Rockville
- Website:
- https://www.neoimmunetech.com/en
Description
NeoImmuneTech, Inc. is a clinical-stage, T cell-focused biopharmaceutical company dedicated to the development of novel immuno-therapeutics. The company's lead asset is NT-I7 (efineptakin alfa), a long-acting human interleukin-7 (IL-7) fusion protein designed to amplify and reinvigorate T cells. This core technology aims to enhance the immune system's ability to eliminate cancer cells and pathogens. NT-I7 is being developed as a foundational immuno-oncology therapy for use in combination with other cancer treatments, such as checkpoint inhibitors, as well as for applications in infectious diseases. The company's research is focused on leveraging T cell amplification to address a wide range of challenging diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2026-01-09 00:00 |
[기재정정]전환청구권행사 (제1회차)
|
Korean | HTML • 14.0 KB | ||
| 2025-12-24 00:00 |
전환청구권행사 (제1회차)
|
Korean | HTML • 11.0 KB | ||
| 2025-12-17 00:00 |
투자판단관련주요경영사항 (겸상적혈구질환 치료제 북미 지역 제반 권리(판매권, 유통권, 상표권 등)에 대한 라이선스 도입…
|
Korean | HTML • 11.7 KB | ||
| 2025-12-16 00:00 |
기타경영사항(자율공시) (제12기 정기주주총회 권리주주 확정을 위한 증권예탁증권 기준일 설정 공고)
|
Korean | HTML • 4.8 KB | ||
| 2025-09-18 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | HTML • 25.0 KB | ||
| 2025-09-18 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | HTML • 94.2 KB | ||
| 2025-09-16 00:00 |
증권발행결과(자율공시) (주주배정 후 실권주 일반공모)
|
Korean | HTML • 7.8 KB | ||
| 2025-09-16 00:00 |
증권발행실적보고서
|
Korean | HTML • 90.0 KB | ||
| 2025-09-15 00:00 |
유상증자또는주식관련사채등의청약결과(자율공시) (주주배정후 실권주 일반공모)
|
Korean | HTML • 11.0 KB | ||
| 2025-09-10 00:00 |
유상증자또는주식관련사채등의청약결과(자율공시) (주주배정후 실권주 일반공모)
|
Korean | HTML • 9.6 KB | ||
| 2025-09-04 00:00 |
유상증자최종발행가액확정 (주주배정후 실권주 일반공모)
|
Korean | HTML • 11.3 KB | ||
| 2025-09-04 00:00 |
[기재정정]주요사항보고서(유상증자결정)
|
Korean | HTML • 38.3 KB | ||
| 2025-09-04 00:00 |
[발행조건확정]증권신고서(증권예탁증권)
|
Korean | HTML • 218.3 KB | ||
| 2025-09-04 00:00 |
[기재정정]투자설명서
|
Korean | HTML • 2.7 MB | ||
| 2025-08-21 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | HTML • 24.2 KB |
Automate Your Workflow. Get a real-time feed of all NeoImmuneTech, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for NeoImmuneTech, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for NeoImmuneTech, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
